Developer docs
API playgroundTry for free, no card

Search company profiles

Yuanbio Ventures

Full company profile

uuid000ff66

Namestring
Yuanbio Ventures
Legal namestring
Suzhou Industrial Park Yuan Fu Venture Capital Limited Partner
Websiteurl
en.bioventure.com.cn
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, biotech investment, medical device investment, venture capital fund management, early stage investment
Industry1 code
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Miscellaneous Financial Investment Activities523999
SIC code1 code
  • Investment Advice6282
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeManaged Services
Description

VC firms typically charge management fees on committed capital during the investment period to cover operations.

en.bioventure.com.cn
2Carried Interest
TypeLicensing Royalties
Description

Profit participation from successful portfolio company exits (IPOs, M&A, secondary sales) generating returns for fund LPs.

en.bioventure.com.cn
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

YuanBio Venture Capital is a healthcare-focused venture capital firm that manages multiple investment funds (YuanBio Fund I, YuanBio USD Fund II) and provides early and growth stage equity investment to innovative healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm invests capital and provides post-investment value-added services including business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 19 portfolio companies listed on STAR Board, HKEX, and Nasdaq
+3 more records
Product overview1 text field

YuanBio Venture Capital is a leading healthcare investment firm offering investment fund management services across four key sectors: biotech/biopharmaceuticals, medical devices, in vitro diagnostics (IVD), and healthcare services. The firm operates multiple fund vehicles (YuanBio Fund I, YuanBio USD Fund II) and has built a portfolio of over 200 companies. Their investment strategy focuses on early and growth stage opportunities with high entry barriers through technology IP, targeting cancer, diabetes, and cardiac disease therapeutics. The firm's value-added services include business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies. The investment operations are structured around portfolio categories (BioPharma, Medical Device, IVD, Health Services), with each category containing multiple invested companies.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1BioBay (苏州生物纳米园)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioBay is YuanBio's core LP and fund sponsor. Located in Suzhou Industrial Park, BioBay brings high-quality deal flow and serves as an information exchange platform. BioBay is a core driver of post-investment value-added services to portfolio companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
15Y Capital (formerly Morningside Venture Capital)
TypeBroad incumbent
Description

China-focused venture firm with healthcare among its core verticals. Has co-invested alongside YuanBio in rounds like Allink Biotherapeutics, and represents an alternative for LPs seeking a fund manager with both healthcare and technology breadth.

2IDG Capital
TypeBroad incumbent
Description

One of the earliest foreign-invested venture capital firms in China, with a dedicated healthcare practice covering biotech, medical devices, and precision medicine. While broader in mandate, IDG competes for the same Chinese healthcare growth-stage opportunities as YuanBio.

3CDH Investments
TypeBroad incumbent
Description

Large Chinese alternative asset manager with a dedicated healthcare practice (RMB 1B fund) and prior follow-on investments in YuanBio portfolio companies (Suzhou Pioneer Pharmaceutical $10M from CDH). Broader mandate but directly overlaps in healthcare growth-stage deals.

4Qiming Venture Partners
TypeDirect peer
Description

One of China's leading healthcare- and technology-focused venture capital firms with a comparable early/growth-stage healthcare practice. Directly competes with YuanBio for healthcare deal flow in China and has similarly demonstrated a strong IPO track record across biotech and medical devices.

5Hillhouse Capital
TypeBroad incumbent
Description

Large China- and Asia-focused investment manager with a substantial healthcare practice alongside consumer and tech investing. While broader than YuanBio, Hillhouse competes for top Chinese healthcare deals and offers institutional LPs an alternative to a pure-play healthcare specialist.

6OrbiMed
TypeBroad incumbent
Description

Global healthcare-dedicated investment firm operating in China with comparable biotech, medtech and diagnostics coverage. Provides an international pure-play alternative to YuanBio for institutional LPs evaluating China healthcare exposure.

7Centurium Capital
TypeDirect peer
Description

Greater China-focused healthcare and growth investor that co-led Excalipoint Therapeutics' extension round with YuanBio. Directly comparable in sector focus and stage strategy, often appearing alongside YuanBio in late-seed/Series A biotech syndicates.

8Legend Capital
TypeDirect peer
Description

China-headquartered venture capital firm with a dedicated healthcare/biotech practice and comparable AUM scale. Legend Capital has co-invested with YuanBio on recent transactions such as Allink Biotherapeutics, making it a direct competitor and frequent co-investor in Chinese healthcare deals.

9Apricot Capital
TypeDirect peer
Description

Healthcare-focused investor that co-led the $41M initial seed round of Excalipoint Therapeutics with YuanBio. Operates a Chinese healthcare mandate at comparable fund size, making it a direct competitor in biotech early-stage financing.

10LYFE Capital (LAV)
TypeDirect peer
Description

Healthcare-dedicated venture capital firm active in China with a focus on innovative therapeutics and medical devices. LYFE participated alongside YuanBio in the Excalipoint Therapeutics extension round, and its fund-stage and sector focus closely parallel YuanBio's strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers27 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yuanbio Ventures

en.bioventure.com.cn

Yuanbio Ventures firmographics

Firmographics
Name
Yuanbio Ventures
Legal name
Suzhou Industrial Park Yuan Fu Venture Capital Limited Partner
Website
https://en.bioventure.com.cn
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Yuanbio Ventures industry classification

Industry
NAICS
Portfolio Management and Investment Advice (52394), Miscellaneous Financial Investment Activities (523999)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Healthcare venture capital
  • Biotech investment
  • Medical device investment
  • Venture capital fund management
  • Early stage investment

Where Yuanbio Ventures is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices5 records

Markets served

Yuanbio Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. Management Fees: VC firms typically charge management fees on committed capital during the investment period to cover operations.
  2. Carried Interest: Profit participation from successful portfolio company exits (IPOs, M&A, secondary sales) generating returns for fund LPs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Yuanbio Ventures product offering

Product offering

Core offering

YuanBio Venture Capital is a healthcare-focused venture capital firm that manages multiple investment funds (YuanBio Fund I, YuanBio USD Fund II) and provides early and growth stage equity investment to innovative healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm invests capital and provides post-investment value-added services including business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies.

Product overview

YuanBio Venture Capital is a leading healthcare investment firm offering investment fund management services across four key sectors: biotech/biopharmaceuticals, medical devices, in vitro diagnostics (IVD), and healthcare services. The firm operates multiple fund vehicles (YuanBio Fund I, YuanBio USD Fund II) and has built a portfolio of over 200 companies. Their investment strategy focuses on early and growth stage opportunities with high entry barriers through technology IP, targeting cancer, diabetes, and cardiac disease therapeutics. The firm's value-added services include business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies. The investment operations are structured around portfolio categories (BioPharma, Medical Device, IVD, Health Services), with each category containing multiple invested companies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 19 portfolio companies listed on STAR Board, HKEX, and Nasdaq
  • +3 more outcomes

Companies that use Yuanbio Ventures

Customer profile

Named customers27 records

Segments4 records

Yuanbio Ventures technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Yuanbio Ventures partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioBay (苏州生物纳米园)coreStrategic or Co-development PartnerBioBay is YuanBio's core LP and fund sponsor. Located in Suzhou Industrial Park, BioBay brings high-quality deal flow and serves as an information exchange platform. BioBay is a core driver of post-investment value-added services to portfolio companies.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Yuanbio Ventures competitors and assessment

Company assessment

Broad incumbents

  • 5Y Capital (formerly Morningside Venture Capital): China-focused venture firm with healthcare among its core verticals. Has co-invested alongside YuanBio in rounds like Allink Biotherapeutics, and represents an alternative for LPs seeking a fund manager with both healthcare and technology breadth.
  • IDG Capital: One of the earliest foreign-invested venture capital firms in China, with a dedicated healthcare practice covering biotech, medical devices, and precision medicine. While broader in mandate, IDG competes for the same Chinese healthcare growth-stage opportunities as YuanBio.
  • CDH Investments: Large Chinese alternative asset manager with a dedicated healthcare practice (RMB 1B fund) and prior follow-on investments in YuanBio portfolio companies (Suzhou Pioneer Pharmaceutical $10M from CDH). Broader mandate but directly overlaps in healthcare growth-stage deals.
  • Hillhouse Capital: Large China- and Asia-focused investment manager with a substantial healthcare practice alongside consumer and tech investing. While broader than YuanBio, Hillhouse competes for top Chinese healthcare deals and offers institutional LPs an alternative to a pure-play healthcare specialist.
  • OrbiMed: Global healthcare-dedicated investment firm operating in China with comparable biotech, medtech and diagnostics coverage. Provides an international pure-play alternative to YuanBio for institutional LPs evaluating China healthcare exposure.

Direct peers

  • Qiming Venture Partners: One of China's leading healthcare- and technology-focused venture capital firms with a comparable early/growth-stage healthcare practice. Directly competes with YuanBio for healthcare deal flow in China and has similarly demonstrated a strong IPO track record across biotech and medical devices.
  • Centurium Capital: Greater China-focused healthcare and growth investor that co-led Excalipoint Therapeutics' extension round with YuanBio. Directly comparable in sector focus and stage strategy, often appearing alongside YuanBio in late-seed/Series A biotech syndicates.
  • Legend Capital: China-headquartered venture capital firm with a dedicated healthcare/biotech practice and comparable AUM scale. Legend Capital has co-invested with YuanBio on recent transactions such as Allink Biotherapeutics, making it a direct competitor and frequent co-investor in Chinese healthcare deals.
  • Apricot Capital: Healthcare-focused investor that co-led the $41M initial seed round of Excalipoint Therapeutics with YuanBio. Operates a Chinese healthcare mandate at comparable fund size, making it a direct competitor in biotech early-stage financing.
  • LYFE Capital (LAV): Healthcare-dedicated venture capital firm active in China with a focus on innovative therapeutics and medical devices. LYFE participated alongside YuanBio in the Excalipoint Therapeutics extension round, and its fund-stage and sector focus closely parallel YuanBio's strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Yuanbio Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yuanbio Ventures leadership team

Management profile

Number of profiles

Yuanbio Ventures subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Yuanbio Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yuanbio Ventures M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuanbio Ventures

What does Yuanbio Ventures do?

YuanBio Venture Capital is a healthcare-focused venture capital firm that manages multiple investment funds (YuanBio Fund I, YuanBio USD Fund II) and provides early and growth stage equity investment to innovative healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm invests capital and provides post-investment value-added services including business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies.

Is Yuanbio Ventures a public or private company?

Yuanbio Ventures is a private company. It is currently operating.

When was Yuanbio Ventures founded?

Yuanbio Ventures was founded in 2013. It employs 101 to 250 people.

Where is Yuanbio Ventures based?

Yuanbio Ventures is headquartered in Suzhou, China, in the Asia region.

How does Yuanbio Ventures make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are Yuanbio Ventures's main competitors?

Broad incumbents on record are 5Y Capital (formerly Morningside Venture Capital), IDG Capital, CDH Investments, Hillhouse Capital and OrbiMed. Direct peers are Qiming Venture Partners, Centurium Capital, Legend Capital, Apricot Capital and LYFE Capital (LAV).

Does Yuanbio Ventures have an API?

No public API is recorded for Yuanbio Ventures.

What industry is Yuanbio Ventures in?

Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0CORE Biomedicine Raises $21 Million Series A And Receives AMED Grant For Cancer ProgramsCORE Biomedicine raised $21 million in Series A financing and received a grant from the Japan Agency for Medical Research and Development (AMED) to advance precision oncology programs based on cancer cell lineage. The venture round was co-led by UTokyo Innovation Platform and Elikon Venture, with participation from InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate, and Root Venture Partners. The funding will support drug discovery and early clinical development of the company's lead programs using a lineage-based approach that targets pathways associated with the cell type from which cancer developed.VC News DailyCORE Biomedicine Scores $21M Series ACORE Biomedicine, a Boston-based biotechnology company developing lineage-based precision oncology therapeutics, announced the completion of a $21 million Series A financing round. The round was co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with participation from multiple venture capital firms including InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. Founded by former leaders of H3 Biomedicine, the company is leveraging a lineage-based approach to target core biological pathways that define cancer cell identity for potential first-in-class therapies.YahooExcalipoint debuts with $68.7m to progress TCE pipelineChinese biotech Excalipoint Therapeutics has emerged with $68.7 million in seed funding to advance its pipeline of T-cell engager (TCE) therapies for immunology and oncology indications. The financing was structured as a $41 million oversubscribed seed round co-led by Apricot Capital, HSG, and Yuanbio Venture Capital, followed by a $27.7 million extension round backed by Lilly Asia Ventures and Eisai Innovation. The company plans to progress six TCE programs including its lead clinical-stage trispecific antibody EXP011, currently in a Phase I/II trial for non-small cell lung cancer and neuroendocrine tumours, and will focus on cross-border partnerships and out-licensing strategies for continued growth.BioSpaceAusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis BAusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio) announced the closing of a $63 million Series B2 financing round co-led by Qiming Venture Partners and an unnamed global strategic investor. The funding will advance the clinical development of AHB-137, the company's lead antisense oligonucleotide candidate for chronic hepatitis B, including ongoing pivotal trials and Phase II combination studies. The round also included participation from HanKang Capital, CDH Investments, YuanBio Venture Capital, Sherpa Capital, and Genesis Capital, with proceeds supporting the Med-Oligo™ ASO platform development and commercial manufacturing scaling.PR NewswirePulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global GrowthPulnovo Medical Limited has successfully closed a financing round led by YuanBio Venture Capital, along with other investors, to support the acceleration of its Pulmonary Artery Denervation FDA-Global Trial and expand its R&D capabilities in cardiopulmonary disease treatment. The amount raised was undisclosed but in the millions of dollars, and Pulnovo aims for approval from China's NMPA for its treatment of pulmonary arterial hypertension in early 2023. The company plans to continue addressing unmet clinical needs and develop innovative product lines for the medical market.BenzingaCash-Strapped Cryofocus Medtech Scrambles to Raise Funds With IPO - Medtronic (NYSE:MDT)Cryofocus Medtech (Shanghai) Co. Ltd., a Chinese maker of minimally invasive medical devices specializing in cryotherapy, has filed for a Hong Kong Stock Exchange IPO, its second attempt after the first failed in January, seeking to raise cash as it posted losses of 159 million yuan (2020) and 126 million yuan (2021) while holding only 129 million yuan in cash by end of April despite having raised 193 million yuan in a Series B round in January. The company needs the capital to fund marketing and expand manufacturing capacity for its bladder cryoablation system, approved in June as one of the first cryotherapy devices for treating bladder cancer to be commercialized globally, with its heart cryoablation system expected to be China's first such approval. Citibank and Huatai International are serving as co-sponsors for the listing, while major investors including Hillhouse Capital (8.48% stake), Yuanbio Venture Capital, and Proxima Ventures have backed the company, whose valuation peaked at 2.09 billion yuan post-Series B but could fall to around 680 million yuan based on comparable unprofitable medtech valuations.MassDeviceAccuPulse raises $10M Series AAccuPulse Medical Technology raised over $10 million in a Series A funding round led by Shenzhen Qianhai Capital, with participation from Shanghai Biomedical Industry Equity Investment Fund and Yuanbio Ventures. The company develops electrophysiology technology for treating cardiac arrhythmias, including an AI-powered 3D mapping system and PFA catheters. AccuPulse intends to use the new capital to finance clinical trials for its PFA system and further product development.Medical BuyerAccuPulse raises $10M Series AAccuPulse Medical Technology announced the closing of a $10 million Series A funding round led by Shenzhen Qianhai Capital, with participation from Shanghai Biomedical Industry Equity Investment Fund and Yuanbio Ventures. The company utilizes this capital to finance clinical trials for its pulsed field ablation system and further product development in electrophysiology. This follows an $8 million pre-Series A raise in 2021 and supports AccuPulse's expansion into U.S. markets.AccupulseAccupulse Raised Tens of Millions RMB in Pre-A FinancingAccuPulse Medical Technology Co. Ltd. completed a Pre-A financing round raising tens of millions of RMB, led by Med-Fine Capital and the Shanghai Biomedical Industry Equity Investment Fund with participation from YuanBio Venture Capital. The company is developing pulsed field ablation (PFA) systems for treating atrial fibrillation, aiming to address the significant unmet clinical needs in China's growing cardiac electrophysiology market. This investment supports AccuPulse's expansion of its R&D capabilities and commercialization efforts for next-generation EP medical devices.PR NewswireIntoCare Medical Completes Up to 100 million RMB Round D Financing, Doubling Down on Powered Stapling IndustryIntoCare Medical Technology completed a Round D financing of up to 100 million RMB, led by Qiming Venture Partners with participation from Oriza Holdings and YuanBio Venture Capital. The company plans to utilize the proceeds for product research and development, clinical research, marketing, and the expansion of new offices and production sites.